The announcement brings Calico’s total funds to $2.5 billion.
Calico and AbbVie started working together in 2014 under the agreement that Calico conducts product research and early-stage development until 2022 and Phase 2a trials through 2027, while AbbVie handles product commercialization and can chose to take on late-stage development. Together, they’ve already created more than 20 early-stage programs to combat diseases in oncology and neuroscience.
More articles on health IT:
Google sets out to organize health records
Disease detection, insurance & more — 8 ways Google may enter healthcare
How Google is using deep learning to understand EHR data and reduce readmissions
